Search Results

Annexon’s late-stage Guillain-Barré syndrome trial has hit its primary endpoint and laid the foundation for a filing for approval next year, the company said Tuesday.

Annexon, Inc. announced that it has commenced an underwritten public offering of $125 million of shares of its common stock.

Annexon, Inc. announced that Douglas Love, president and chief executive officer, will present at the Bank of America Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT.

Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

Annexon, Inc. announced the pricing of its previously announced underwritten public offering of 13,001,120 shares of its common stock at a price to the public of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 7,000,000 shares of common stock at a purchase price of $6.249 per share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant.

Annexon, Inc. announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

Annexon, Inc., a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, highlighted portfolio progress and reported first quarter 2024 financial results.

Annexon, Inc. today announced it will host a virtual R&D Day on Friday, March 1, 2024 at 10:00 AM ET.

Annexon, Inc. today announced that it will host a conference call and webcast on Tuesday, June 4, 2024, at 8:30 a.m. ET to discuss GBS phase 3 data.

Annexon, Inc. (Nasdaq: ANNX), today announced positive results from the completed pivotal Phase 3 trial of C1q-targeted immunotherapy, ANX005, in Guillain-Barré Syndrome (GBS) at the 2024 Peripheral Nerve Society (PNS) Annual Meeting in Montréal, Canada.